As of Friday close, bluebird bio Inc.’s (NASDAQ:BLUE) stock was up $0.2, moving up 5.93 percent to $3.57. The average number of shares traded per day over the past five days has been 3,009,780 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.16 fall in that time frame. In the last twenty days, the average volume was 2,459,930, while in the previous 50 days, it was 2,512,154.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
Since last month, BLUE stock retreated -26.54%. Shares of the company fell to $3.11 on 05/12/22, the lowest level in the past month. A 52-week high of $23.04 was reached on 01/04/22 after having rallying from a 52-week low of $3.11. Since the beginning of this year, BLUE’s stock price has dropped by -64.26% or -$6.42, and marked a new high 2 times. However, the stock has declined by -84.50% since its 52-week high.
bluebird bio Inc. (BLUE) last reported insider trading activity 123 days ago on Jan 11. Cole Jason, the Chief Operating and of the company, disposed of 3,387 shares for $9.64 on Jan 11. It resulted in a $32,659 divestment by the insider. Leschly Nick sold 5,068 shares at an average price of $9.64 on Jan 11. The insider now owns 281,330 shares following the transaction. On Jan 11, President and CEO Obenshain Andrew sold 4,683 shares at $9.64 apiece. The transaction was valued at $45,156.
The stock’s beta is 1.64. Besides these, the trailing price-to-sales (P/S) ratio of 75.04, the price-to-book (PB) ratio of 0.66.
In the three months ended March 30, bluebird bio Inc.’s quick ratio stood at 2.20, while its current ratio was 2.20, showing that the company is able to pay off its debt. Based on annual data, BLUE earned -$35.2 million in gross profit and brought in $3.66 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -157.90%. Return on equity (ROE) for the past 12 months was -95.60%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. BLUE’s revenue fell -449.23% to -$35.88 million during the quarter, while net income inched up to $1.95 million. While analysts expected bluebird bio Inc. to report -$1.39 quarterly earnings, the actual figure was -$1.66 per share, beating the consensus estimate by -19.40%. During the quarter, the company generated -$119.33 million in EBITDA. The liabilities of bluebird bio Inc. were 227.81 million at the end of its most recent quarter ended March 30, and its total debt was $89.58 million. The value of shareholders’ equity is $71.45 million.
This quick technical analysis looks at bluebird bio Inc.’s (BLUE) price momentum. With a historical volatility rate of 163.11%, the RSI 9-day stood at 44.55% on 13 May.
With respect to its five-day moving average, the current bluebird bio Inc. price is down by -4.29% percent or -$0.16. At present, BLUE shares trade -21.37% below its 20-day simple moving average and -66.67% percent below its 100-day simple moving average. However, the stock is currently trading approximately -31.48% below its SMA50 and -86.09% below its SMA200.
Stochastic coefficient K was 20.35% and Stochastic coefficient D was 21.39%, while ATR was 0.40. Given the Stochastic reading of 34.57% for the 14-day period, the RSI (14) reading has been calculated as 43.12%. As of today, the MACD Oscillator reading stands at -0.35, while the 14-day reading stands at -0.36.
bluebird bio Inc. downgraded its rating on bluebird bio Inc. (NASDAQ: BLUE) to a Market perform in a note to investors on April 06, 2022. The analysts firm previously had an Outperform rating on the stock.bluebird bio Inc. (BLUE) has been rated Underweight by analysts. According to 3 brokerage firms , BLUE is a sell, and 9 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate bluebird bio Inc. stock as buy, with 0 recommending it as overweight.